CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to (1) evaluate pain-free efficacy of Treximet™ following
treatment of menstrual migraine, (2) investigate levels of Calcitonin gene-related peptide
(CGRP), estrogen, cortisol, vasoactive intestinal peptide (VIP), alpha (a)-amylase,
Prostaglandin E2 (PGE2), Prostaglandin I2 (PGI2) and beta (ß)-endorphin in saliva before and
after Treximet™, (3) evaluate efficacy of Treximet™ to return to baseline levels following
treatment, and (4) correlate estrogen in saliva vs. urinary estradiol at mid-luteal, onset of
menstrually-related migraine, and after successful treatment with Treximet™.